Abstract
Therapeutically, one of the most fruitful discoveries in pharmacopsychiatry was of the prophylactic effect of chronic lithium administration in patients with affective and schizoaffective disorders. Although this therapy represents an important step, several problems remain as yet unresolved: One is the partial or non-response of about 30% of patients with affective psychoses and of about 50% of patients with schizoaffective psychoses; another is the problem of side effects and, resulting from this, noncompliance. For this reason the introduction of the anticonvulsants valproate and carbamazepine for pharmacological treatment of affective disorders was important since these compounds apparently have a lithium-like clinical profile of action. An especially challenging question regarding alternatives to lithium prophylaxis arises because of the relatively low therapeutic efficacy of lithium in schizoaffective psychoses: from a differential-therapeutic perspective, the question of which alternative to lithium may be regarded as a promising candidate in treatment of lithium-resistant schizoaffective psychoses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baastrup PC, Schou M (1967) Lithium as a prophylactic agent. Arch Gen Psychiatry 16: 162–172
Ballenger JC, Post RM (1980) Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137: 782–790
Dose M, Apelt S, Emrich HM (1987) Carbamazepine as adjunct of antipsychotic therapy. Psychiatry Res 22: 303–310
Dunner DL, Fieve RR (1974) Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30: 229–233
Emrich HM, Cording C, Pirée S, Kölling A, von Zerssen D, Herz A (1977) Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmacopsychiatry 10: 265–270
Emrich HM, von Zerssen D, Kissling W, Möller H-J, Windorfer A (1980) Effect of sodium valproate on mania — The GABA hypothesis of affective disorders. Arch Psychiatr Nervenkr 229: 1–16
Emrich HM, Dose M, von Zerssen D (1985) The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affective Disord 8: 243–250
Emrich HM, Wendl A, Zihl J (1988) Die Wirkung von Lithium auf die Dunkeladaptation. In: Beckmann H, Laux G (eds) Biologische Psychiatrie. Synopsis 1986/87. Springer, Berlin Heidelberg New York, pp 382–384
Goodnick PJ, Fieve RR, Schlegel A, Baxter N (1987) Predictors of interepisode symptoms and relapse in affective disorder patients treatment with lithium carbonate. Am J Psychiatry 144: 367–369
Inoue K, Arima S, Tanaka K, Fukui Y, Kato N (1981) A lithium and carbamazepine combination in the treatment of bipolar disorder — a preliminary report. Folia Psychiatr Neurol Jpn 35: 465–475
Kukopulos A, Reginaldi D, Laddomada G, Floris G, Serra G, Tondo L (1980) Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry 13: 156–167
Lambert PA, Carraz G, Borselli S, Carrel S (1966) Action neuropsychotrope d’un nouvel antiepileptique: le Dépamide. Ann Med Psychol (Paris) 1: 707–710
McElroy S, Keck PE Jr, Pope HG, Hudson JI (1988) Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 8: 275–279
Misra PC, Burns BH (1977) “Lithium non-responders” in a lithium clinic. Acta Psychiat Scand 55:32–40
Nolen WA (1983) Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand 67: 218–225
Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A, Matsushita T, Nakao T, Ogura C (1973) Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiat Neurol Jpn 27: 283–297
Post RM, Uhde TW, Ballenger JC, Squillace KM (1983) Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 140: 1602–1604
Post RM, Uhde TW, Wolff EA (1984) Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its 10,11-epoxide metabolite. Acta Psychiat Scand 69 (Suppl 313): 104–120
Prien RF, Caffey EM Jr, Klett CJ (1974) Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 31: 189–192
Shukla S, Cook BL, Miller MG (1985) Lithium-carbamazepine versus lithium-neuroleptic prophylaxis in bipolar illness. J Affective Disord 9: 219–222
Strömgren LS, Boller S (1985) Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiat Dev 4: 349–367
Takezaki H, Hanaoka M (1971) The use of carbamazepine ( Tegretol) in the control of manic-depressive psychoses and other manic-depressive states. Clin Psychiatry 13: 173–183
Wehr TA, Goodwin FK (1979) Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36: 555–559
Zerssen D von, Dirlich G, Fischler M (1983) Influence of an abnormal time routine and therapeutic measures on 48-hour cycles of affective disorders: chronobiological considerations. In: Wehr TA, Goodwin FK (eds) Circadian rhythms in psychiatry. Boxwood, Pacific Grove CA, pp 109–127
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Emrich, H.M. (1990). Alternatives to Lithium Prophylaxis for Affective and Schizoaffective Disorders. In: Marneros, A., Tsuang, M.T. (eds) Affective and Schizoaffective Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75353-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-75353-4_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75355-8
Online ISBN: 978-3-642-75353-4
eBook Packages: Springer Book Archive